Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NeoTrio trial: what clinicians have said so far
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma
- NCT02858921 ↗
- Active, not recruiting
- Melanoma Institute Australia
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NeoTrio (BRAF V600-mutant resectable stage III melanoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NeoTrio so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X, typically up to 26 once built | |
| 1 YouTube video, typically up to 4 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C/D (Excluding In-transit) Melanoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Melanoma
- Interventions
- Dabrafenib; Trametinib; Pembrolizumab
- Arms
- Sequential D + T, THEN Pembrolizumab · Experimental
- Concurrent D + T AND Pembrolizumab · Experimental
- Pembrolizumab ONLY · Experimental
- Enrollment
- 60
- Primary outcomes
- Pathological Response Rate
- Sponsor
- Melanoma Institute Australia with Merck Sharp & Dohme LLC, Novartis
- Start
- Nov 8, 2017
- Primary completion
- Jan 2, 2022
- Results posted
- Yes
- Registry record
- NCT02858921 · updated Aug 24, 2026
Publications
linked from the registry- Long GV, Carlino MS, Au-Yeung G, Spillane AJ, Shannon KF, Gyorki DE, Hsiao E, Kapoor R, Thompson JR, Batula I, Howle J, Ch'ng S, Gonzalez M, Saw RPM, Pennington TE, Lo SN, Scolyer RA, Menzies AM. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial. Nat Med. 2024 Sep;30(9):2540-2548. doi: 10.1038/s41591-024-03077-5. Epub 2024 Jun 21. PubMed 38907159
- Gorry C, McCullagh L, O'Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Neoadjuvant treatment for stage III and IV cutaneous melanoma. Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2. PubMed 36648215